Rabbit Recombinant Monoclonal SARS CoV-2 ORF9b protein antibody. Carrier free. Suitable for WB, I-ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
WB | I-ELISA | |
---|---|---|
Recombinant fragment - SARS-CoV-2 | Tested | Tested |
SARS-CoV-2 | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Plays a role in inhibiting the host innate immune response by targeting the mitochondrial-associated innate immune response. Acts by binding to host TOMM70, inhibiting its binding to HSP90AB1 thereby disrupting the interferon activation pathway.
SARS CoV-2 ORF9b protein
ORF9b protein, ORF9b, Accessory protein 9b, ORF-9b, Protein 9b, 9b
Rabbit Recombinant Monoclonal SARS CoV-2 ORF9b protein antibody. Carrier free. Suitable for WB, I-ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab284049 is the carrier-free version of ab284935
Protein 9b and ORF9b are alternative names for Uniprot P0DTD2.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The SARS-CoV-2 ORF9b protein sometimes referred to as ORF9b protein is a small accessory protein with a mass of approximately 9 kDa. This protein is encoded by the open reading frame 9b (ORF9b) of the SARS-CoV-2 virus. It is expressed within the infected host cells where the virus replicates. ORF9b protein localizes to the mitochondria and plays a structural role in modulating host cellular processes during infection.
The ORF9b protein interacts with the host immune system by inhibiting the type I interferon signaling pathway. This protein acts as a part of the viral evasion mechanisms allowing SARS-CoV-2 to escape host immune detection. ORF9b does not form part of a larger protein complex by itself but operates through interactions with host proteins affecting the host's antiviral responses.
ORF9b disrupts the type I interferon immune signaling pathway one of the host's key antiviral defenses. It interacts with proteins such as Tom70 a mitochondrial import receptor. This interaction hampers the signaling cascade leading to reduced production of interferon which normally activates immune responses against viral infections. ORF9b's role in these pathways directly counteracts the host's ability to mount a timely defense against SARS-CoV-2 infection.
ORF9b is associated with the pathogenesis of COVID-19 the disease caused by SARS-CoV-2. Its ability to suppress immune signaling can contribute to the severity of COVID-19 by enabling viral persistence and exacerbating inflammatory responses. Additionally ORF9b interaction with ubiquitin system proteins such as MAVS facilitates immune evasion highlighting its role in the disease progression and severity.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035, the same antibody clone in a different buffer formulation.
Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035 was shown to bind specifically to SARS-CoV-2 ORF9b protein in Western blot. Samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
Anti-GST antibody [3G10/1B3] ab92 is a Mouse monoclonal [3G10/1B3] to GST
Blocking buffer: 3% milk in TBS-0.1% Tween® 20 (TBS-T)
All lanes: Western blot - Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] (Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035) at 1/1000 dilution
All lanes: Recombinant SARS-CoV2 ORF9b protein (GST-tagged) at 0.2 µg
Lane 1: Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution
Lane 2: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Observed band size: 37 kDa
Indirect ELISA- Anti-SARS-CoV2 ORF9b Protein Antibody (Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035)
Indirect ELISA showing primary antibody Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035 binding to recombinant SARS-CoV-2 ORF9b protein. Plates were coated with recombinant SARS-CoV-2 ORF9b protein (GST-tagged) and recombinant SARS-CoV-2 ORF3 protein (His-tagged) at 1000 ng/ml. Binding of Anti-SARS-CoV-2 Protein 9b antibody [EPR25043-28] ab284035 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution).
Binding was detected using pre-adsorbed secondary antibody, goat anti-rabbit IgG H&L (HRP, Goat Anti-Rabbit IgG H&L (HRP) preadsorbed ab97080) at 1/2000 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com